Skip to content

Early Extracorporeal Shockwave Therapy for Erectile Dysfunction in Radically Prostatectomised Men.

Early Extracorporeal Shockwave Therapy for Erectile Dysfunction in Radically Prostatectomised Men.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04059341
Enrollment
70
Registered
2019-08-16
Start date
2019-09-01
Completion date
2020-07-01
Last updated
2019-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction, Extracorporeal Shockwave Therapy, Radical Prostatectomy

Keywords

Radical Prostatectomy, Prostatectomy, Nerve-sparing, Non nerve-sparing, Erectile dysfunction, Erectile function, Shockwave, LI-ESWT, ESWT, Low intensity extracorporeal shockwave therapy, extracorporeal shockwave therapy

Brief summary

The purpose of this project is to assess the relationship between low intensity shock wave treatment (LI-SWT) and erectile function (ED) in patients who have undergone radical prostatectomy (RP).

Interventions

DEVICELow Intensity Extracorporeal Shockwave Therapy (LI-ESWT)

Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.

Sponsors

Odense University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Sham LI-ESWT treatment.

Intervention model description

Randomised, single-blinded, placebo-controlled trial

Eligibility

Sex/Gender
MALE
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Radically prostatectomised men * Non nerve-sparing or nerve-sparing RP. * Age 20-80 years * Have been in a relationship for more than 3 months. * Sexually active * Patient can give informed consent.

Exclusion criteria

* Men with ED of neuropathological or psychogenic origin * Rectal extirpation, radiation therapy to the pelvic area and recovery from any other cancer within the past 5 years are excluded. * Patients with heart disease prohibiting sexual activity or taking medication with antiandrogens, anticoagulant (apart from aspirin) or systemic use of glucocorticoids within 5 weeks.

Design outcomes

Primary

MeasureTime frameDescription
IIEF-5 Score 1One month after final treatment sessionChange in International Index of Erectile Function (IIEF-5) score compared to baseline
IIEF-5 Score 3Three months after final treatment sessionChange in International Index of Erectile Function (IIEF-5) score compared to baseline
IIEF-5 Score 6Six months after final treatment sessionChange in International Index of Erectile Function (IIEF-5) score compared to baseline

Secondary

MeasureTime frameDescription
EHS 3Three months after final treatment sessionChange in Erection Hardness Score compared to baseline
EDITSOne month after final treatment sessionErectile Dysfunction Inventory of Treatment Satisfaction score
EHS 6Six months after final treatment sessionChange in Erection Hardness Score compared to baseline
RigiScanOne month after final treatment sessionChange in nocturnal erections compared to baseline
EHS 1One month after final treatment sessionChange in Erection Hardness Score compared to baseline

Countries

Denmark

Contacts

Primary ContactAli Moumneh, BSC.med
almou15@student.sdu.dk+45234826423
Backup ContactLars Lund, Professor
lars.lund@rsyd.dk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026